194 related articles for article (PubMed ID: 16221151)
1. Impairment of renal function after islet transplant alone or islet-after-kidney transplantation using a sirolimus/tacrolimus-based immunosuppressive regimen.
Andres A; Toso C; Morel P; Demuylder-Mischler S; Bosco D; Baertschiger R; Pernin N; Bucher P; Majno PE; Bühler LH; Berney T
Transpl Int; 2005 Nov; 18(11):1226-30. PubMed ID: 16221151
[TBL] [Abstract][Full Text] [Related]
2. Impact of a sirolimus/tacrolimus-based immunosuppressive regimen on kidney function after islet transplantation.
Andres A; Toso C; Morel P; Demuylder-Mischler S; Bosco D; Baertschiger R; Pernin N; Bucher P; Majno PE; Bühler LH; Berney T
Transplant Proc; 2005 Mar; 37(2):1326-7. PubMed ID: 15848711
[TBL] [Abstract][Full Text] [Related]
3. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
[TBL] [Abstract][Full Text] [Related]
4. Comparison of sirolimus alone with sirolimus plus tacrolimus in type 1 diabetic recipients of cultured islet cell grafts.
Gillard P; Ling Z; Mathieu C; Crenier L; Lannoo M; Maes B; Roep B; Gorus F; Pipeleers D; Keymeulen B
Transplantation; 2008 Jan; 85(2):256-63. PubMed ID: 18212631
[TBL] [Abstract][Full Text] [Related]
5. Islet of Langerhans allogeneic transplantation at the University of Geneva in the steroid free era in islet after kidney and simultaneous islet-kidney transplantations.
Berney T; Bucher P; Mathe Z; Andres A; Bosco D; Mage R; Toso C; Oberholzer J; Becker C; Philippe J; Bühler L; Morel P
Transplant Proc; 2004 May; 36(4):1121-2. PubMed ID: 15194390
[TBL] [Abstract][Full Text] [Related]
6. Improved metabolic control and quality of life in seven patients with type 1 diabetes following islet after kidney transplantation.
Cure P; Pileggi A; Froud T; Messinger S; Faradji RN; Baidal DA; Cardani R; Curry A; Poggioli R; Pugliese A; Betancourt A; Esquenazi V; Ciancio G; Selvaggi G; Burke GW; Ricordi C; Alejandro R
Transplantation; 2008 Mar; 85(6):801-12. PubMed ID: 18360260
[TBL] [Abstract][Full Text] [Related]
7. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
DuBay D; Smith RJ; Qiu KG; Levy GA; Lilly L; Therapondos G
Liver Transpl; 2008 May; 14(5):651-9. PubMed ID: 18433069
[TBL] [Abstract][Full Text] [Related]
8. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T
Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
[TBL] [Abstract][Full Text] [Related]
9. Sirolimus in kidney transplantation from marginal donors.
Pisani F; Buonomo O; Iaria G; Iorio B; Rizzello A; Pollicita S; De Luca L; Valeri M; Boffo V; Famulari A; Casciani CU
Transplant Proc; 2004 Apr; 36(3):495-6. PubMed ID: 15110569
[TBL] [Abstract][Full Text] [Related]
10. Improvement in renal function and rejection control in pediatric liver transplant recipients with the introduction of sirolimus.
Casas-Melley AT; Falkenstein KP; Flynn LM; Ziegler VL; Dunn SP
Pediatr Transplant; 2004 Aug; 8(4):362-6. PubMed ID: 15265163
[TBL] [Abstract][Full Text] [Related]
11. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
[TBL] [Abstract][Full Text] [Related]
12. The combination of sirolimus and cyclosporine does not delay initial renal graft function recovery.
Hsu HJ; Tian YC; Chen YC; Lai BC; Fang JT; Yang CW; Wu MS
Ren Fail; 2008; 30(3):303-6. PubMed ID: 18350450
[TBL] [Abstract][Full Text] [Related]
13. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
[TBL] [Abstract][Full Text] [Related]
14. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.
Watson CJ; Gimson AE; Alexander GJ; Allison ME; Gibbs P; Smith JC; Palmer CR; Bradley JA
Liver Transpl; 2007 Dec; 13(12):1694-702. PubMed ID: 18044728
[TBL] [Abstract][Full Text] [Related]
15. Successful use in lung transplantation of an immunosuppressive regimen aimed at reducing target blood levels of sirolimus and tacrolimus.
Villanueva J; Boukhamseen A; Bhorade SM
J Heart Lung Transplant; 2005 Apr; 24(4):421-5. PubMed ID: 15797743
[TBL] [Abstract][Full Text] [Related]
16. Can daclizumab reduce acute rejection and improve long-term renal function in tacrolimus-based primary renal transplant recipients?
Cheung CY; Liu YL; Wong KM; Chan HW; Chan YH; Wong HS; Chak WL; Choi KS; Chau KF; Shek CC; Li CS
Nephrology (Carlton); 2008 Jun; 13(3):251-5. PubMed ID: 18221256
[TBL] [Abstract][Full Text] [Related]
17. Impact of sirolimus treatment in kidney allograft recipients with prolonged cold ischemia times: 5-year outcomes.
Boratynska M; Banasik M; Patrzalek D; Klinger M
Exp Clin Transplant; 2008 Mar; 6(1):59-66. PubMed ID: 18405247
[TBL] [Abstract][Full Text] [Related]
18. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus.
Albano L; Berthoux F; Moal MC; Rostaing L; Legendre C; Genin R; Toupance O; Moulin B; Merville P; Rerolle JP; Bayle F; Westeel PF; Glotz D; Kossari N; Lefrançois N; Charpentier B; Blanc AS; Di Giambattista F; Dantal J;
Transplantation; 2009 Jul; 88(1):69-76. PubMed ID: 19584683
[TBL] [Abstract][Full Text] [Related]
19. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
Bemelman FJ; de Maar EF; Press RR; van Kan HJ; ten Berge IJ; Homan van der Heide JJ; de Fijter HW
Transplantation; 2009 Aug; 88(3):421-8. PubMed ID: 19667948
[TBL] [Abstract][Full Text] [Related]
20. Insulin independence after conversion to tacrolimus and sirolimus-based immunosuppression in islet-kidney recipients.
Toso C; Morel P; Bucher P; Mathe Z; Demuylder-Mischler S; Bosco D; Berney T; Oberholzer J; Shapiro J; Oberholzer J; Philippe J
Transplantation; 2003 Oct; 76(7):1133-4. PubMed ID: 14557767
[No Abstract] [Full Text] [Related]
[Next] [New Search]